# A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults

> **NCT07768345** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 440 (estimated)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **BIOLOGICAL:** RSVpreF Vaccine

## Key facts

- **NCT ID:** NCT07768345
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2028-02-02
- **Final completion:** 2028-02-02
- **Target enrollment:** 440 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07768345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07768345, "A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07768345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
